Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Provided By GlobeNewswire
Last update: May 8, 2025
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025
Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone)
Read more at globenewswire.comNASDAQ:CING (10/20/2025, 2:28:26 PM)
3.82
+0.12 (+3.24%)
NASDAQ:CINGW (10/20/2025, 2:08:03 PM)
0.0555
+0.01 (+21.98%)
Find more stocks in the Stock Screener
